We improve diagnosis, prognosis and treatment of cancer
Patients should only undergo medical procedures that are meaningful and necessary. No woman should have unjustified worries about getting cervical cancer and every cancer patient is taken care off with effective treatment protocols only.
Patient oriented
Personalizing diagnosis and prognosis is paramount to us.
Cooperative & efficient
We listen to patients and communicate with doctors to provide them with best possible treatment suggestions.
Reliable & objective
Predica provides objective treatment suggestions based on computer algorithms with proven value.
Our mission:
To prevent overdiagnosis and overtreatment of cancer by predicting the best treatment for cancer patients.
Learn how Predica Diagnostics accomplishes this by checking our technology
Our Products
Predica Diagnostics BV uses the proprietary ciRNAseq technology. The CervicaDX assay, based on this technology, is developed and marketed to non-invasively assess the risk to develop cervical cancer and to guide proper treatment.
The CervicaDx assay will prevent overdiagnosis and overtreatment of women, participating in cervical cancer screening programs, by detecting cervical aberrations before they can develop into cancer, with much higher specificity than is currently feasible.
News
We are pleased to share our latest white paper, A Successful Combination: The Ellele Device from Ellele Health and the HPV Profiler from Predica Diagnostics, the result of a scientific collaboration between Ellele Health and Predica Diagnostics.
This paper outlines a novel approach to cervical cancer screening, combining a speculum-free biospecimen collection device with a high-specificity molecular HPV test. Key highlights include:
A user- and clinician-preferred alternative to conventional sampling
High-quality samples suitable for DNA-based testing
Promising potential to improve detection of high-risk HPV and CIN2+ lesions
Together, these innovations offer a pathway toward more accessible, patient-centric, and diagnostically robust cervical screening.
We are pleased to share our latest white paper, A Successful Combination: The Ellele Device from Ellele Health and the HPV Profiler from Predica Diagnostics, the result of a scientific collaboration between Ellele Health and Predica Diagnostics.
This paper outlines a novel approach to cervical cancer screening, combining a speculum-free biospecimen collection device with a high-specificity molecular HPV test. Key highlights include:
A user- and clinician-preferred alternative to conventional sampling
High-quality samples suitable for DNA-based testing
Promising potential to improve detection of high-risk HPV and CIN2+ lesions
Together, these innovations offer a pathway toward more accessible, patient-centric, and diagnostically robust cervical screening.
Predica Diagnostics BV is proud to join Tech4Eva - The global Femtech accelerator !
Predica was selected as one of the 16 companies out of 195 start-ups from 42 countries.
We look forward to engage with other companies in this great 2025 cohort: GICMED, LAYCO, MedSol AI Solutions, menoQueens, MoleSense, oasicare, Powerly, RephImmune Biotechnology, Salva Health, Silatha, Smartweave Inc, TIMSER GROUP, Woost, Xemperia, XENA.
Thanks to Simone Theiss and Lan Zuo Gillet for the great support !
